DE-105

**DE-105** is an investigational ophthalmic neurotrophic-factor peptide formulation originally developed by Santen Pharmaceutical for **persistent corneal epithelial defects**, particularly defects associated with impaired corneal sensory innervation. The exact peptide sequence, molecular target, and receptor-level pharmacology have not been publicly disclosed in the identified primary sources. It is intended to promote corneal epithelial repair and restoration of the ocular surface. Santen completed a Phase 2 study of DE-105 ophthalmic solution in persistent corneal epithelial defect, and R-Tech Ueno subsequently acquired development and commercialization rights in 2015.

Other names

DE-105 ophthalmic solutionDE105 ophthalmic solutionDE 105 ophthalmic solutionFGLM-amide